BioNTech SE
corporate_fare Company Profile
BioNTech SE (NASDAQ:BNTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for BNTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BNTX spans 6-K, 144.
Recent high-impact activity:
- Pumitamig Plus Docetaxel Shows 36.7% ORR, 6.9-Month PFS in 2L NSCLC
- BioNTech's Trastuzumab Pamirtecan Meets Phase 3 PFS Endpoint, But Modest Benefit and Higher ILD
- Phase 3 Breast Cancer Win Is Modest, With Higher Lung-Inflammation Rate
- BioNTech Taps Gilead's Trodelvy for Phase 3 Pumitamig TNBC Combination
- BioNTech's BNT113 Misses PFS Endpoint in Phase 2/3 Head and Neck Cancer Trial
Financial Snapshot
Short Interest & Short Volume
2.06 days to coverFINRA reported short interest of 2,272,174 shares in BNTX as of the October 15, 2026 settlement, a 9.0% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On October 30, 2026, 35.7% of BNTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
BNTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.